Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition

@article{Dresser2000PharmacokineticPharmacodynamicCA,
  title={Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition},
  author={G. Dresser and J. Spence and D. Bailey},
  journal={Clinical Pharmacokinetics},
  year={2000},
  volume={38},
  pages={41-57}
}
Drug interactions occur when the efficacy or toxicity of a medication is changed by administration of another substance. Pharmacokinetic interactions often occur as a result of a change in drug metabolism. Cytochrome P450 (CYP) 3A4 oxidises a broad spectrum of drugs by a number of metabolic processes. The location of CYP3A4 in the small bowel and liver permits an effect on both presystemic and systemic drug disposition. Some interactions with CYP3A4 inhibitors may also involve inhibition of P… Expand
Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring
TLDR
To minimize drug-drug interactions involving mechanism-based CYP3A4 inhibition, it is necessary to choose safe drug combination regimens, adjust drug dosages appropriately, and conduct therapeutic drug monitoring for drugs with narrow therapeutic indices. Expand
The role of pharmacokinetics, drug interactions and pharmacogenetics in the acquired long QT syndrome
TLDR
It is prudent that all new entities under investigation (and their significant metabolites) be screened for the potential to cause torsade de pointes. Expand
Inhibition of Cytochrome P450 3A: Relevant Drug Interactions in Gastroenterology
TLDR
P Practitioners have to be aware of the high potential of metabolic drug interactions when they prescribe a CYP3A inhibitor, and it is wise to check carefully comedication in patients complaining of side effects with substrates of CYP 3A. Expand
Clinical outcomes and management of mechanism-based inhibition of cytochrome P 450 3 A 4
Mechanism-based inhibition of cytochrome P450 (CYP) 3A4 is characterized by NADPH-, time-, and concentration-dependent enzyme inactivation, occurring when some drugs are converted by CYPs to reactiveExpand
Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4
TLDR
A good understanding of CYP3A4 inactivation and proper clinical management are needed by clinical professionals when these drugs are used and predicting the risks for potential drug–drug interactions is needed. Expand
The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
TLDR
Although genotype tests can determine if a patient has a specific enzyme polymorphism, it has not been determined if routine use of these tests will improve outcomes and knowledge of the most important drugs metabolized by cytochrome P450 enzymes, as well as the most potent inhibiting and inducing drugs, can help minimize the possibility of adverse drug reactions and interactions. Expand
Effect of Inhibition of Cytochrome P450 Enzymes 2D6 and 3A4 on the Pharmacokinetics of Intravenous Oxycodone
TLDR
The results of this study indicate that there are no clinically relevant drug interactions with intravenous oxycodone and inhibitors of CYP2D6 and inhibition of both oxidative metabolic pathways via CYP3A4 and 2D6 are inhibited. Expand
Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs
TLDR
It appears that the chemical properties of a drug critical to CYP3A4 inactivation include formation of reactive metabolites by CYP isoenzymes, preponderance of CYP inducers and P-glycoprotein (P-gp) substrate, and occurrence of clinically significant pharmacokinetic interactions with coadministered drugs. Expand
Inhibition of Human Cytochrome P450 Isoforms by Nonnucleoside Reverse Transcriptase Inhibitors
TLDR
In vitro microsomal model provides relevant predictive data on probable drug interactions with NNRTIs when the mechanism is inhibition of CYP‐mediated drug biotransformation, however, the model does not incorporate interactions attributable to enzyme induction. Expand
Pharmacokinetic Aspects of Treating Infections in the Intensive Care Unit
TLDR
Hydrophilic anti-infective agents are often eliminated unchanged by renal glomerular filtration and tubular secretion, and are therefore involved in competition for excretion, and there is a risk of nephrotoxicity and neurotoxicity with some cephalosporins and carbapenems. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 150 REFERENCES
Inhibition and Induction of Cytochrome P450 and the Clinical Implications
TLDR
T careful evaluation of potential drug interactions of a new drug candidate during the early stage of drug development is essential, because the smaller the difference between toxic and effective concentration, the greater the likelihood that a drug interaction will have serious clinical consequences. Expand
Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?
TLDR
In the treatment of transplant patients, from a drug interaction perspective, pravastatin, which is not significantly metabolized by CYP enzymes, and fluvastatin compare favorably with the other statins for which the major metabolic pathways are catalyzed by CyP3A. Expand
Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.
TLDR
The HIV protease inhibitors have differential effects on CYP isozymes and there is obvious potential for clinically significant drug interactions particularly with ritonavir. Expand
P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.
TLDR
Results demonstrate that, although many P-gp inhibitors are potent inhibitors of CYP3A, a varying degree of selectivity is present and the development and use of P-GP inhibitors with minimal or absent CYP2A inhibitory effects should decrease the impact of drug interactions on the therapeutic use of such compounds. Expand
In vitro and in vivo drug interactions involving human CYP3A.
TLDR
Cytochrome P4503A (CYP3A) is importantly involved in the metabolism of many chemically diverse drugs administered to humans and makes it a major contributor to presystemic elimination following oral drug administration. Expand
The effect of fluconazole on the steady‐state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans
TLDR
It is concluded that a pharmacokinetic interaction between terfenadine and fluconazole exists; however, the absence of accumulation of parent terfendine in plasma suggests that a clinically significant interaction is unlikely. Expand
Prolongation of the QT Interval Related to Cisapride‐Diltiazem Interaction
TLDR
A possible drug interaction occurred in a 45‐year‐old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension, where the patient was in near syncope and had QT‐interval prolongation. Expand
Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole.
TLDR
An in vitro-in vivo scaling model predicted a decrement of triazolam clearance due to ketoconazole coadministration that was consistent with the 88% decrement in clearance actually observed in vivo. Expand
Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6)
TLDR
This study examined the effect of clarithromycin on pimozide pharmacokinetics and QT interval changes in a total of 12 healthy subjects, documented as extensive metabolizers or poor metabolizers of CYP2D6. Expand
Carbamazepine drug interactions.
TLDR
Studies and case reports demonstrate that CBZ may accelerate the metabolism of phenytoin, phenobarbital (PB), primidone, valproic acid, and warfarin, and pheny toin, PB, and primid one may increase the hepatic metabolism of CBZ. Expand
...
1
2
3
4
5
...